Business Context and Reporting Period
Company: ImageneBio, Inc. (formerly Ikena Oncology, Inc.)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: ImageneBio is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases. The company's sole product candidate is IMG-007, a non-depleting anti-OX40 monoclonal antibody currently in Phase 2b development for atopic dermatitis (AD).
Corporate Structure Change: On July 25, 2025, the company completed a reverse recapitalization merger with Legacy Inmagene Biopharmaceuticals. Concurrently, the company divested its non-IMG-007 assets (the "Non-OX40 Business") to a related party, Miragene Inc., to focus exclusively on the OX40 program.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| License Revenue | $0.8 million | $3.5 million |
| Net Loss | $(45.3) million | $(36.6) million |
| Research & Development Expenses | $28.5 million | $32.1 million |
| General & Administrative Expenses | $20.7 million | $8.4 million |
| Cash, Cash Equivalents & Marketable Securities (Dec 31, 2025) | $135.3 million | $12.1 million |
| Accumulated Deficit (Dec 31, 2025) | $(230.1) million | $(179.9) million |
Note: The company has not generated any revenue from product sales. Revenue is derived solely from license agreements.
Material Changes vs. Prior Period
- Merger and Capital Raise: The 2025 period includes the reverse recapitalization with Ikena Oncology and a PIPE financing that raised approximately $75.0 million. This significantly increased cash reserves from $12.1 million in 2024 to $135.3 million in 2025.
- Divestiture: The company divested all non-IMG-007 assets (including BTK and CSF-1R programs) to Miragene Inc. in exchange for a promissory note valued at approximately $7.0 million (fair value) and cash.
- Expense Fluctuations:
- R&D Expenses: Decreased by $3.6 million (11%) primarily due to the absence of a $14.0 million non-cash stock issuance expense related to the Hutchmed Agreement option exercise in 2024, partially offset by increased stock-based compensation ($10.4 million) and clinical development costs.
- G&A Expenses: Increased by $12.3 million (147%) driven by higher stock-based compensation ($5.0 million), professional fees ($3.2 million), and wages/benefits ($2.5 million) associated with the merger and public company operations.
- Revenue Decline: License revenue dropped 77% to $0.8 million, reflecting the settlement of the IMG-008 agreement ($0.8 million) compared to the $3.5 million upfront payment from the IMG-013 agreement in 2024.
Guidance, Outlook, and Risks
Outlook and Clinical Progress
- IMG-007 Clinical Status: A multi-country Phase 2b dose-finding study in atopic dermatitis (AD) began in 2025. Topline data is expected in 2027.
- Proof of Concept: Phase 1b/2a data showed 54% of patients achieving EASI-75 and 31% achieving EASI-90 by Week 16, with durable inhibition of inflammatory markers.
- Liquidity: Management believes current cash resources ($135.3 million) are sufficient to fund operations for at least the next 12 months.
Material Risks and Contingencies
- Internal Control Weakness: The company identified a material weakness in internal control over financial reporting related to a lack of segregation of duties in journal entries and account reconciliations. Remediation is in progress but not yet complete.
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding to complete clinical development and commercialization.
- Manufacturing Dependence: The company relies entirely on third-party contract manufacturers (currently Wuxi Biologics) for drug substance and product. Supply chain disruptions or regulatory actions (e.g., BIOSECURE Act) could impact operations.
- Intellectual Property: Rights to IMG-007 are licensed from Hutchmed. Failure to meet diligence obligations or milestone payments could result in termination of the license.
- Legal Proceedings: Two shareholder lawsuits regarding the merger registration statement were filed in June 2025 but were voluntarily dismissed in February 2026.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $135.3 million cash balance against the projected burn rate for the Phase 2b trial and potential future capital raises.
- Internal Controls: Monitor the remediation plan for the identified material weakness in financial reporting to ensure future financial statement reliability.
- Clinical Milestones: Track the progress of the Phase 2b ADAPTIVE trial and the timeline for 2027 topline data readout.
- Manufacturing Supply: Assess the risks associated with reliance on a single Chinese manufacturer (Wuxi Biologics) in light of evolving U.S. trade policies and the BIOSECURE Act.
- Licensing Obligations: Review the Hutchmed Agreement terms regarding milestone payments (up to $92.5 million) and royalty obligations to ensure the company can meet these financial commitments upon success.